VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

S-268019
Vaccine Information
  • Manufacturer: Shionogi
  • Vaccine Ontology ID: VO_0005096
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823 (Hashimoto et al., 2022)
Host Response

Monkey Response

  • Immune Response: Two weeks after the second dosing, dose-dependent humoral immune responses were observed with neutralizing antibody titers being comparable to that of human convalescent plasma. (Hashimoto et al., 2022)
  • Side Effects: No adverse clinical signs or weight loss associated with the vaccine were observed, suggesting safety of the vaccine in cynomolgus monkeys.
References
Hashimoto et al., 2022: Masayuki Hashimoto 1, Noriyo Nagata 2, Tomoyuki Homma 3, Hiroki Maeda 4, Keiji Dohi 5, Naomi M Seki 6, Ken Yoshihara 7, Naoko Iwata-Yoshikawa 8, Nozomi Shiwa-Sudo 9, Yusuke Sakai 10, Masayuki Shirakura 11, Noriko Kishida 12, Tomoko Arita 13, Yasushi Suzuki 14, Shinji Watanabe 15, Hideki Asanuma 16, Takuhiro Sonoyama 17, Tadaki Suzuki 18, Shinya Omoto 19, Hideki Hasegawa 20. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. . 2022; ; . [PubMed: 35691872].